



NAMRU-2



HEMOGLOBIN G HSI-TSOU: 379 Asp-Gly



NAMRU-2-TR-494
1972

United States Naval
Medical Research Unit No. Two
Taipei, Taiwan

Reproduced by
**NATIONAL TECHNICAL
INFORMATION SERVICE**
Springfield, Va. 22151

**BEST
AVAILABLE COPY**

101	WHITE SECTION ☒
102	BUFF SECTION ☐
103	INDICES ☐
104	IDENTIFICATION
BY	
DISTRIBUTION/AVAILABILITY CODES	
DIST.	AVAIL. CODE/SPECIAL
A	26

BIOCHEMISTRY DEPARTMENT

R. QUENTIN BLACKWELL, Ph.D., HEAD

ADMINISTRATIVE INFORMATION

THE WORK WAS ACCOMPLISHED UNDER THE U.S. NAVY BUREAU OF MEDICINE AND SURGERY WORK UNIT MR005.20.01-00998. THE STUDY WAS SUPPORTED IN PART BY THE BUREAU OF MEDICINE AND SURGERY, DEPARTMENT OF THE NAVY, WASHINGTON, D. C., AND IN PART BY THE ADVANCED RESEARCH PROJECT AGENCY (PROJECT AGILE) WITH FUNDS MONITORED BY THE NUTRITION PROGRAM, NATIONAL CENTER FOR CHRONIC DISEASE CONTROL, U. S. PUBLIC HEALTH SERVICE, DHEW, UNDER ARPA ORDER NO. 580, PROGRAM PLAN 298.

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED

.....

R. H. WATTEN
CAPT MC USN
COMMANDING OFFICER

UNCLASSIFIED

Security Classification

DOCUMENT CONTROL DATA - R & D

Security classification of title, body of abstract and indexing annotation must be entered when the overall report is classified

1. ORIGINATING ACTIVITY (Corporate author)		2a. REPORT SECURITY CLASSIFICATION	
U. S. NAVAL MEDICAL RESEARCH UNIT No. 2 Box 14, APO SAN FRANCISCO 96263		UNCLASSIFIED	
3. REPORT TITLE		2b. GROUP	
HEMOGLOBIN G Hsi-Tsou: $\beta 79$ ASP $\rightarrow$ GLY			
4. DESCRIPTIVE NOTES (Type of report and inclusive dates)			
TECHNICAL REPORT			
5. AUTHOR(S) (First name, middle initial, last name)			
R. QUENTIN BLACKWELL, T.-B. SHIH, C.-L. WANG, AND C.-S. LIU			
6. REPORT DATE	7a. TOTAL NO OF PAGES	7b. NO OF REFS	
1972	5	17	
8a. CONTRACT OR GRANT NO	9a. ORIGINATOR'S REPORT NUMBER(S)		
b. PROJECT NO	NAMRU-2-TR-494		
c. MR005.20.01-0099B.	9b. OTHER REPORT NO(S) (Any other numbers that may be assigned this report)		
d.			
10. DISTRIBUTION STATEMENT			
DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED			
11. SUPPLEMENTARY NOTES		12. SPONSORING MILITARY ACTIVITY	
PUBLISHED IN BIOCHIM. BIOPHYS. ACTA 257: 49-53, 1972		BUREAU OF MEDICINE AND SURGERY DEPARTMENT OF THE NAVY WASHINGTON, D. C. 20390	
13. ABSTRACT			
HB G Hsi-Tsou WAS FOUND IN TAIWAN, IN 1964, IN TWO CHINESE SISTERS WHO WERE BORN IN HOPEI PROVINCE. STRUCTURE ANALYSES NOW HAVE SHOWN THAT THE ANOMALY IN THIS VARIANT IS AT THE $\beta 79$ OR βEF_3 POSITION WHERE A GLYCYL GROUP REPLACES THE ASPARTYL GROUP NORMALLY PRESENT AT THAT LOCATION. ANOTHER HEMOGLOBIN VARIANT FOUND IN CHINESE SUBJECTS, HB G TAICHUNG, PREVIOUSLY HAS BEEN REPORTED TO HAVE THE STRUCTURE CHANGE ASP $\rightarrow$ HIS AT THE CORRESPONDING LOCATION IN THE α CHAIN, POSITION αEF_3 OR $\alpha 74$. IN THE INOX CASE SEPARATIONS OF THE HEMOGLOBIN FRACTIONS BY CHROMATOGRAPHY WITH DEAE-SEPHADEX COLUMN REVEALED THAT THE RELATIVE AMOUNTS OF HBS A₀ AND G Hsi-Tsou WERE 54 AND 46%, RESPECTIVELY. PRESENCE OF H₃G Hsi-Tsou IN THE HETEROZYGOTE APPARENTLY CAUSES NO ANEMIA.			

Security Classification

DD FORM 1473 (BACK)
(PAGE 2)

UNCLASSIFIED
Security Classification

Reprinted from

Biochimica et Biophysica Acta

Elsevier Publishing Company, Amsterdam · Printed in The Netherlands

BBA 35993

HEMOGLOBIN G HSI-TSOU: $\beta 79$ Asp $\rightarrow$ Gly*

R. QUENTIN BLACKWELL, T.-B. SHIH, C.-L. WANG AND C.-S. LIU

*Department of Biochemistry**, U.S. Naval Medical Research Unit No. 2, Taipei, Taiwan (Republic of China)*

(Received July 26th, 1971)

SUMMARY

Hb G Hsi-Tsou was found in Taiwan, in 1964, in two Chinese sisters who were born in Hopei Province. Structure analyses now have shown that the anomaly in this variant is at the $\beta 79$ or $\beta EF3$ position where a glycyl group replaces the aspartyl group normally present at that location. Another hemoglobin variant found in Chinese subjects, Hb G Taichung, previously has been reported to have the structure change Asp $\rightarrow$ His at the corresponding location in the α chain, Position $\alpha EF3$ or $\alpha 74$.

In the index case separations of the hemoglobin fractions by chromatography with DEAE-Sephadex column revealed that the relative amounts of Hbs A_0 and G Hsi-Tsou were 54 and 46%, respectively. Presence of HbG Hsi-Tsou in the heterozygote apparently causes no anemia.

INTRODUCTION

A hemoglobin variant¹ with the singly slow electrophoretic mobility in alkaline pH characteristic of G hemoglobins was found in one female Chinese adult during a population survey¹ in 1964. Recently the variant, named G Hsi-Tsou, was examined by chemical structure studies and found to have a single amino acid substitution in the $\beta T9$ peptide. As described below, the aspartyl group normally present at Position $\beta 79$ (helical No. EF3) is replaced by a glycyl group; accordingly, Hb G Hsi-Tsou may be represented as $\alpha_2\beta_2^{79} \text{ Asp} \rightarrow \text{Gly}$.

MATERIALS AND METHODS

The index subject with Hb G Hsi-Tsou was a 45-year-old Chinese woman who was born in Hopei Province of mainland China. A sister of the index subject

* The opinions and assertions contained herein are those of the authors and are not to be construed as official or reflecting the views of the U.S. Navy Department or the U.S. Naval Service at large.

** Mailing address from U.S.: Publications Office, U.S. Naval Medical Research Unit No. 2, Box 14, APO San Francisco, Calif. 96263, U.S.A.

also was found to have the variant. In both cases the subjects were heterozygotes with mixtures of hemoglobins A and G.

The standard methods of chemical structural analysis used in the present study have been described in previous reports²⁻⁷.

RESULTS AND DISCUSSION

The blood hemolysate was examined by starch-gel electrophoresis⁸ at pH 8.9 and both Hbs A and G were present. Electrophoresis of the mixture on cellogel⁹ showed the G hemoglobin to have an anomalous β -chain. The hemoglobin mixture was separated by column chromatography¹⁰ with DEAE-Sephadex A-50-120 using a Tris-HCl gradient buffer system⁷. The two major components were measured spectrophotometrically in the column effluent and the ratio of Hb A₀ to Hb G was 54 to 46.

Hemoglobin G Hsi-Tsou was subjected to tryptic digestion²⁻⁶ and the peptide mixture examined by mapping^{11,12}. The ninhydrin-stained map (Fig. 1) appeared normal except that the spot generally occupied by peptide β T₉, Position 1, was missing and a new spot was present at Position 2.

For further analytical work the abnormal peptide, β^G T₉, was separated⁷ from the other tryptic peptides by electrophoresis on paper for 2.5 h at 3000 V using pyridine-acetate buffer at pH 5.4, followed by additional electrophoresis at 5000 V for 1.5 h using formate buffer at pH 1.9. For comparative studies normal peptide β^A T₉




Fig. 1. Peptide map made from tryptic digest of purified globin from Hb G Hsi-Tsou. Details of electrophoresis and chromatography procedures used for mapping have been described in previous reports⁴⁻⁶; 0.2% ninhydrin was used for staining. Peptide β^A T₉, which normally is found at Position 1 on the map, is missing. Parallel to that position chromatographically but displaced to the left electrophoretically is the new spot at Position 2. As described in the text, the new peptide at Position 2 was found to have nearly the same amino acid composition as β^A T₉, except for one more glycyl acid and one less aspartyl group, and was called β^G T₉. The faint staining pattern of the new peptide, like that normally found for peptide β^A T₉, is due to the occurrence of a valyl residue at the N-terminal position. The increased cathodal mobility of peptide β^G T₉ compared with that of β^A T₉ results from replacement of one aspartyl group by a glycyl group; the changed mobility matches the slower electrophoretic mobility, in starch gel at alkaline pH, of Hb G Hsi-Tsou compared with that of Hb A₀.

AMINO ACID COMPOSITION OF NORMAL β T₉ PEPTIDE FROM Hb A₀ COMPARED WITH THAT OF THE ABNORMAL β T₉ PEPTIDE FROM Hb G HAI-TSUO

^a Including one Asn residue.

partyl residues¹². As shown in Fig. 2, five peptides should be produced by this treatment of peptide $\beta^A T_9$. These include two larger peptides: the neutral hexapeptide from Position β -67 to β -72 and the basic pentapeptide from β -74 to β -78. All five of the peptides were found. In addition, free aspartic acid was identified; it was released from Positions β -73 and β -79 by the selective hydrolysis¹² of the $\beta^A T_9$ peptide under the relatively mild hydrolytic conditions provided at 110° by 0.03 M HCl. All five peptides from $\beta^A T_9$ had the expected amino acid compositions. No sequence studies were made on the five peptides but amounts of individual amino acids were determined in selected peptides¹⁴. For example, the basic pentapeptide contained one glycine, two leucines, one alanine and one histidine. From these data and the known sequence of peptide $\beta^A T_9$ it was assumed that the pentapeptide had the structure Gly-Leu-Ala-His-Leu. Significantly, as described below, this peptide was not found in $\beta^G T_9$ except as part of a larger peptide.



Peptide $\beta^G T_9$

Fig. 3. Peptide $\beta^G T_9$, like $\beta^A T_9$, contains 16 amino acid residues from valyl at Position β -67 to lysyl at β -82. From experimental results described in the text, Gly replaces Asp at Position β -79. The vertical dashed lines indicate the peptide bonds which would be expected to undergo specific cleavage from hydrolysis with 0.03 M HCl hydrolysis¹².

The same study of peptides released by selective cleavage of aspartyl bonds in peptide $\beta^G T_9$ produced differences (Fig. 3). Four peptides were found on the peptide map instead of the five for peptide $\beta^A T_9$. One neutral hexapeptide had the same map location and the same amino acid composition as the neutral hexapeptide from peptide $\beta^A T_9$ and was judged to be Val-Leu-Gly-Ala-Phe-Ser from positions β -67 to β -72. Its presence indicated selective cleavage between Positions β -72 and β -73 and thereby showed that the aspartyl group must still be at Position β -73 in $\beta^G T_9$ peptide as it is in $\beta^A T_9$ peptide. The basic pentapeptide Gly-Leu-Ala-His-Leu described above as present in $\beta^A T_9$ was not present in the $\beta^G T_9$; in its place was a basic peptide containing two glycine and two leucine groups and one each of alanine and histidine. This was assumed to be the hexapeptide Gly-Leu-Ala-His-Leu-Gly which would represent Positions β -74 to β -79 in $\beta^G T_9$ including the new glycyl residue at position β -79 replacing the aspartyl group found at that position in $\beta^A T_9$. In addition there was a basic peptide containing glycine, leucine, alanine, histidine, asparagine (aspartic acid after hydrolysis with 5.7 M HCl prior to amino acid analysis) and lysine. This was assumed to be the larger peptide, illustrated in Fig. 3, extending from glycine at Position β -74 to C-terminal lysine at β -82. The basic dipeptide leucyllysine, representing Positions β -81 and β -82, also was found as in peptide $\beta^A T_9$. Its presence confirms the hydrolytic cleavage between Positions 80 and 81. No tripeptide containing aspartyl or asparaginyl along with leucine and lysine was found and none would be expected in the absence of aspartyl at Position β -79.

Taken together the above structural data indicate that of the two possible positions, β -73 and β -79, it is the latter position where glycyl replaces aspartyl in Hb G Hsi-Tson.

Hb G Hsi-Tson represents the second hemoglobin variant known to involve the β -79 or β EF3 position. The original G hemoglobin reported in 1954 by EDINGTON AND LEHMANN¹⁵ was later called G Acra and shown¹⁶ to be β 79 Asp $\rightarrow$ Asn. Another variant found in Chinese subjects, Hb G Taichung, has the change Asp $\rightarrow$ His at the α -74 or α EF3 position¹⁷.

Thus far no other subjects except the two sisters described above have been found with Hb G Hsi-Tson. The variant apparently causes no anemia in the carrier.

ACKNOWLEDGEMENTS

We thank Misses J. T.-H. Huang and Linda Ting for collecting the blood samples used in the present study and Miss Helen Hsin for performing the quantitative amino acid analyses.

The work was accomplished under the U. S. Navy Bureau of Medicine and Surgery Work Unit MR005.20.01-0090B. The study was supported in part by the Bureau of Medicine and Surgery, Department of the Navy, Washington, D.C., and in part by the Advanced Research Project Agency (Project AGILE) with funds monitored by the Nutrition Program, National Center for Chronic Disease Control, U. S. Public Health Service, DHEW, under ARPA Order No. 580, Program Plan 298.

REFERENCES

- 1 R. Q. BLACKWELL AND J. T.-H. HUANG, *Abstr. 12th Cong. Int. Soc. Hematol., New York, 1968*, p. 53.
- 2 R. Q. BLACKWELL AND C. S. LIU, *Biochem. Biophys. Res. Commun.*, **24** (1966) 732.
- 3 R. Q. BLACKWELL AND C. S. LIU, *Biochem. Biophys. Res. Commun.*, **30** (1968) 690.
- 4 R. Q. BLACKWELL, H.-J. YANG AND C.-C. WANG, *Biochim. Biophys. Acta*, **175** (1969) 237.
- 5 R. Q. BLACKWELL, H.-J. YANG AND C.-C. WANG, *Biochim. Biophys. Acta*, **185** (1969) 59.
- 6 R. Q. BLACKWELL, H.-J. YANG AND C.-C. WANG, *Biochim. Biophys. Acta*, **194** (1969) 1.
- 7 R. Q. BLACKWELL, C.-S. LIU AND T.-B. SHIH, *Biochim. Biophys. Acta*, **229** (1971) 343.
- 8 R. Q. BLACKWELL AND J. T.-H. HUANG, *Clin. Chem.*, **11** (1965) 628.
- 9 J. ROSA, D. LABIE, H. WAJCMAN, J. M. BOIGNE, R. CABANNES, R. BIERME AND J. RUFFIE, *Nature*, **223** (1969) 190.
- 10 T. H. J. HUISMAN AND A. M. DOZY, *J. Chromatogr.*, **19** (1965) 160.
- 11 V. M. INGRAM, *Biochim. Biophys. Acta*, **28** (1958) 539.
- 12 C. BAGLIONI, *Biochim. Biophys. Acta*, **48** (1961) 392.
- 13 M. A. NAUGHTON, F. SANGER, B. S. HARTLEY AND D. C. SHAW, *Biochem. J.*, **77** (1960) 149.
- 14 F. ROTHMAN AND A. HIGA, *Anal. Biochem.*, **3** (1962) 173.
- 15 G. M. EDINGTON AND H. LEHMANN, *Lancet*, **ii** (1954) 173.
- 16 H. LEHMANN, D. BEALE AND F. S. BOI-DOKU, *Nature*, **203** (1964) 363.
- 17 R. Q. BLACKWELL AND C. S. LIU, *Biochim. Biophys. Acta*, **200** (1970) 70.

Biochim. Biophys. Acta, **257** (1972) 49-53